Introduction and Aims: There is no active treatment for post-renal transplant BK virus associated nephropathy (BKVAN) that has proven to be effective so far.
LONG TERM FOLLOW UP OF ACTIVE MANAGEMENT VERSUS MINIMIZATION OF IMMUNOSUPPRESSIVES OF BK VIRUS ASSOCIATED NEPHROPATHY AFTER A KIDNEY TRANSPLANT
Medhat Abdel Halim1, Torki Al-Otaibi1, Osama Gheith1, Ahmed Mosaad1, Zakaria Zakaria1, Tarek Said1, Prasad Nair1 and Mrn Nampoory1 1 Ibn Sina Hospital, Medical, Kuwait, Kuwait Introduction and Aims: There is no active treatment for post-renal transplant BK virus associated nephropathy (BKVAN) that has proven to be effective so far. We aimed to assess effectiveness of active management of BKVAN with combined leflunomide, IVIG and ciprofloxacin on the long term graft outcome compared to minimization of immunosuppressives. Methods: Our kidney transplant recipients were screened for BKVAN. Group1 (n=22): was composed of kidney transplant recipients with twice positive BK virus-PCR in
urine and blood who underwent graft biopsy to confirm BKVAN. Once BKVAN is diagnosed, anti-metabolite (mycophenolate mofetil or azathioprine) was changed to leflunomide and a course of IVIG and oral ciprofloxacin were given. Group 2(n=33): was composed of BKVAN patients treated conventionally with reduced immunosuppressives. Results: Fifty five patients were treated, 69%were males, 50.9% were diabetics, mean HLA mismatches was 3.65 and 50.9% of patients were CW7 negative. All patients received induction therapy (thymoglobulin in 55.6%) and 52.7% received antirejection therapy before BKVAN diagnosis. Maintenance immunosuppression was prednisolone (96.3%), mycophenolate mofetil (94.5%) and tacrolimus (50.9%). Subsequent rejection episodes have occurred in 38% of the patients after BKVAN diagnosis. Basal mean eGFR was 52.5±25.5 which has reduced significantly to 38.1±27.8 ml/min/1.73m2 ( p
